Current problems in cancer · 2026
End-of-induction MRD predicts early survival in high-risk adult B-acute lymphoblastic leukemia: A study from Eastern India.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Prakhar, Tyagi Meghna, Brahma Subhajit, Ghosh Shouriyo, Podder Dibakar, Chattopadhyay Debranjani, Kumar Jeevan, Nag Arijit, Nair Reena, Rath Asish, Vinarkar Sushant, Parihar Mayur, Mishra Deepak Kumar
Аннотация
UNLABELLED: Measurable residual disease (MRD) monitoring has dramatically improved outcomes in pediatric acute lymphoblastic leukemia (ALL) patients while, the prognosis in adult B-ALL remains poor. Biological heterogeneity, therapy-related toxicity, and inconsistent MRD-integration contribute to this disparity. This study evaluates the early prognostic value of MRD by flow cytometry in high-risk adult B-ALL patients.
METHODS: The present study included 47 high-risk adult B-ALL patients stratified by cytogenetic-risk groups (Age range: 18 - 66 years) and treated between January 2020 and December 2024 at Tata Medical Center, Kolkata. MRD was assessed using an 11-color flow cytometry panel at end-of-induction (EOI) and end-of-consolidation (EOC) timepoints. Patient details including demographics, cytogenetic risk profiles, treatment protocols, and survival outcomes were collected. Statistical analysis was performed using univariable, multivariable (MANNOVA) and multivariable cox-regression tests. Kaplan-Meier analysis was performed for survival at 18-months.
RESULTS: At EOI time point, 27 patients were MRD-negative, while 20 had detectable MRD (4 low-level <0.01%, 16 high-level ≥0.01%). MRD positivity at EOI significantly correlated with inferior survival at 18 months (log-rank p = 0.004). On univariable cox regression, EOI MRD positive patients demonstrated an approximately six-fold higher hazard of relapse or death compared with MRD-negative patients (HR = 6.33; 95% CI, 0.39-103.07). Multivariable and cox-regression analysis confirmed EOI MRD positivity as an independent predictor of OS (p = 0.004). Additionally, Day 8 prednisone response showed prognostic significance with survival (cox-regression p-value = 0.003; MANNOVA p ≈ 0.05).
CONCLUSIONS: The EOI MRD positivity, is a robust independent predictor of 18m-survival in high-risk adult B-ALL patients. Additionally, a longitudinal MRD monitoring enhances risk stratification and informs therapeutic decisions. Therefore, incorporating MRD assessment into routine clinical practice is essential for dynamic risk stratification and optimizing outcomes in High-risk adult B-ALL.
METHODS: The present study included 47 high-risk adult B-ALL patients stratified by cytogenetic-risk groups (Age range: 18 - 66 years) and treated between January 2020 and December 2024 at Tata Medical Center, Kolkata. MRD was assessed using an 11-color flow cytometry panel at end-of-induction (EOI) and end-of-consolidation (EOC) timepoints. Patient details including demographics, cytogenetic risk profiles, treatment protocols, and survival outcomes were collected. Statistical analysis was performed using univariable, multivariable (MANNOVA) and multivariable cox-regression tests. Kaplan-Meier analysis was performed for survival at 18-months.
RESULTS: At EOI time point, 27 patients were MRD-negative, while 20 had detectable MRD (4 low-level <0.01%, 16 high-level ≥0.01%). MRD positivity at EOI significantly correlated with inferior survival at 18 months (log-rank p = 0.004). On univariable cox regression, EOI MRD positive patients demonstrated an approximately six-fold higher hazard of relapse or death compared with MRD-negative patients (HR = 6.33; 95% CI, 0.39-103.07). Multivariable and cox-regression analysis confirmed EOI MRD positivity as an independent predictor of OS (p = 0.004). Additionally, Day 8 prednisone response showed prognostic significance with survival (cox-regression p-value = 0.003; MANNOVA p ≈ 0.05).
CONCLUSIONS: The EOI MRD positivity, is a robust independent predictor of 18m-survival in high-risk adult B-ALL patients. Additionally, a longitudinal MRD monitoring enhances risk stratification and informs therapeutic decisions. Therefore, incorporating MRD assessment into routine clinical practice is essential for dynamic risk stratification and optimizing outcomes in High-risk adult B-ALL.